QLGN: The configuration of the Crypto Assets accomplice account has been completed, and the purchase of the first batch of CXC 10 strategic assets will start this week.
According to Mars Finance, Nasdaq-listed company Qualigen Therapeutics (QLGN) announced that it has completed the establishment of infrastructure such as USD cash settlement, bank accounts, and crypto asset custody accounts over the past two weeks, and will officially begin purchasing its first batch of strategic assets this week, primarily investing in the top 10 crypto assets by market capitalization, focusing on “blue chip” crypto assets including BNB, ETH, and SOL. Previously, it was reported that FF has made a strategic investment of $41 million in Nasdaq-listed company QLGN, and Jia Yueting invested $4 million, with QLGN set to be renamed CXC 10.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
QLGN: The configuration of the Crypto Assets accomplice account has been completed, and the purchase of the first batch of CXC 10 strategic assets will start this week.
According to Mars Finance, Nasdaq-listed company Qualigen Therapeutics (QLGN) announced that it has completed the establishment of infrastructure such as USD cash settlement, bank accounts, and crypto asset custody accounts over the past two weeks, and will officially begin purchasing its first batch of strategic assets this week, primarily investing in the top 10 crypto assets by market capitalization, focusing on “blue chip” crypto assets including BNB, ETH, and SOL. Previously, it was reported that FF has made a strategic investment of $41 million in Nasdaq-listed company QLGN, and Jia Yueting invested $4 million, with QLGN set to be renamed CXC 10.